Page 16 from the Webinar is a bit concerning IMO with this comment (see below ADC extract) "Implementation of required preclinical studies to demonstrate proof-of-concept" ... what has Merck been doing for the last 3 years ??? Weren't they undertaking these preclinical studies with ADCs ? Are we starting all over again ....doesn't say much for our supposed partner Merck ?
Perhaps that's why Merck went with Daiichi Sankyo and committed up to $22 billion for their ADCs .... they obviously weren't that impressed or they would have signed a deal with us surely after all this research (3 Years) ?
Merck bags chance to test ADCs based on Starpharma delivery tech
Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform.
Last year, Merck struck a deal to perform a preclinical evaluation of dendrimer-based ADCs made using Starpharma’s DEP delivery technology. The deal cleared Merck to take a close look at the fruits of a drug delivery platform that is designed to yield ADCs with greater homogeneity, site specific attachment and higher drug-antibody ratios than conventional candidates.
